Nuclear Medicine and Biology
Volume 35, Issue 1 , Pages 29-34 , January 2008

A change of in vivo characteristics depending on specific activity of radioiodinated (+)-2-[4-(4-iodophenyl)piperidino]cyclohexanol [(+)-pIV] as a ligand for sigma receptor imaging

  • Nasima Akhter

      Affiliations

    • Department of Biotracer Medicine, Kanazawa University, Kanazawa 920-8640, Ishikawa, Japan
    • ,
  • Kazuhiro Shiba

      Affiliations

    • Division of Tracer Kinetics, Advanced Science Research Center, Kanazawa University, Kanazawa 920-8640, Ishikawa, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 76 265 2474; fax: +81 76 234 4245.
    • ,
  • Kazuma Ogawa

      Affiliations

    • Division of Tracer Kinetics, Advanced Science Research Center, Kanazawa University, Kanazawa 920-8640, Ishikawa, Japan
    • ,
  • Shiro Tsuji

      Affiliations

    • School of Health Sciences, Kanazawa University, Kanazawa 920-8640, Ishikawa, Japan
    • ,
  • Seigo Kinuya

      Affiliations

    • Department of Biotracer Medicine, Kanazawa University, Kanazawa 920-8640, Ishikawa, Japan
    • ,
  • Kenichi Nakajima

      Affiliations

    • Department of Biotracer Medicine, Kanazawa University, Kanazawa 920-8640, Ishikawa, Japan
    • ,
  • Hirofumi Mori

      Affiliations

    • Division of Tracer Kinetics, Advanced Science Research Center, Kanazawa University, Kanazawa 920-8640, Ishikawa, Japan

Received 9 August 2007 ,Revised 12 September 2007 ,Accepted 27 September 2007.

References 

  1. Martin WR, Eades CG, Thompson JA, Huppler RE, Gilber PE. The effects of morphine and morphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther. 1976;197:517–532
  2. Walker JM, Bowen WD, Walker FO, Matsumoto RR, de Costa B, Rice KC. Sigma receptors: biology and function. Pharmacol Rev. 1990;42:355–402
  3. Quirion R, Bowen WD, Itzhak Y, Junien JL, Musacchio JM, Rothman R, et al. A proposal for the classification of σ-binding sites. Trends Pharmacol Sci. 1992;13:85–86
  4. Weissman AD, Su T-P, Hedreen JC, London ED. Sigma receptors in post-mortem human brains. J Pharmacol Exp Ther. 1988;247:29–33
  5. Su T-P. Delineating biochemical and functional properties of sigma receptors: emerging concepts. Crit Rev Neurobiol. 1993;7:187–203
  6. Maurice T, Hiramatsu M, Itoh J, Kameyama T, Hasegawa T, Nabeshima T. Behavioral evidence for a modulating role of sigma ligands in memory processes: I. Attenuation of dizocilpine (MK-801)-induced amnesia. Brain Res. 1994;647:44–56
  7. Jansen KL, Faull RL, Storey P, Leslie RA. Loss of sigma binding sites in the CA1 area of the anterior hippocampus in Alzheimer's disease correlates with CA1 pyramidal cell loss. Brain Res. 1993;623:299–302
  8. Helmeste DM, Tang SW, Bunney WE, Potkin SG, Jones EG. Decrease in sigma but no increase in striatal dopamine D4 sites in schizophrenic brains. Eur J Pharmacol. 1996;314(3):R3–R5
  9. Simpson MDC, Slater P, Royston MC, Deakin JFW. Alterations in phencyclidine and sigma binding sites in schizophrenic brains. Effects of disease process and neuroleptic medication. Schizophr Res. 1992;6:41–48
  10. Weissman ED, Casanova MF, Kleinman JE, London ED, De Souza EB. Selective loss of cerebral cortical sigma, but not PCP binding sites in schizophrenia. Biol Psychiatry. 1991;29:41–54
  11. Collier TL, Waterhouse RN, Kassiou M. Imaging sigma receptors: applications in drug development. Curr Pharm Des. 2007;13(1):51–72
  12. John CS, Bowen WD, Saga T, Kinuya S, Vilner BJ, et al. A malignant melanoma imaging agent: synthesis, characterization, in vitro binding and biodistribution of iodine-125-(2-piperidinylaminoethyl)-4-iodobenzamide. J Nucl Med. 1993;34:2169–2175
  13. Choi SR, Yang B, Plossl K, Chumpradit S, Wey S, Acton PD, et al. Development of a Tc-99m labeled sigma-2 receptor-specific ligand as a potential breast tumor imaging agent. Nucl Med Biol. 2001;28:657–666
  14. Waterhouse RN, Mardon K, Giles KM, LeeCollier T, O'Brien JC. Halogenated 4-(phenoxymethyl)piperidines as potential radiolabeled probes for σ-1 receptors: in vivo evaluation of [123I]-1-(iodopropen-2-yl)-4-[(4-cyanophenoxy)methyl]piperidine. J Med Chem. 1997;40:1657–1667
  15. Waterhouse RN, Mardon K, O'Brien JC. Synthesis and preliminary evaluation of [123I]1-(4-cyanobenzyl)-4-[(trans-iodopropen-2-yl)oxymethyl]piperidine: a novel high affinity sigma receptor radioligand for SPECT. Nucl Med Biol. 1997;24:45–51
  16. Waterhouse RN, Chapman J, Izard B, Donald A, Belbin K, et al. Examination of four 123I-labeled piperidine-based sigma receptor ligands as potential melanoma imaging agents: initial studies in mouse tumor models. Nucl Med Biol. 1997;24:587–593
  17. Collier T, O'Brien JC, Waterhouse RN. Synthesis of [18F]-1-(3-fluoropropyl)-4-(4-cyanophenoxymethyl)piperidine: a potential sigma-a receptor radioligand for PET. J Label Compd Radiopharm. 1996;38:785–794
  18. Waterhouse RN, Collier TL. In vivo evaluation of [18F]-1-(3-fluoropropyl)-4-(4-cyanophenoxymethyl)piperidine: a selective sigma-1 receptor radioligand for PET. Nucl Med Biol. 1997;24:127–134
  19. Dence CS, John CS, Bowen WD, Welch MJ. Synthesis and evaluation of [18F] labeled benzamides: high affinity sigma receptor ligands for PET imaging. Nucl Med Biol. 1997;24:333–340
  20. Shiue CY, Shiue GG, Zhang SX, Wilder S, Greenberg JH, Benard F, et al. N-(N-Benzylpiperidine-4-yl)-2-[18F]fluoro-benzamide: a potential ligand for PET imaging of σ receptors. Nucl Med Biol. 1997;24:671–676
  21. Ishiwata K, Noguchi J, Ishii S, Hatano K, Ito K, Nabeshima T, et al. Synthesis and preliminary evaluation of [11C]NE-100 labeled in two different positions as a PET σ receptor ligand. Nucl Med Biol. 1998;2:195–202
  22. Kawamura K, Ishiwata K, Shimada Y, Kimura Y, Kobayashi T, Matsuno K, et al. Preclinical evaluation of [11C]SA4503: radiation dosimetry, in vivo selectivity and PET imaging of sigma-1 receptors in the cat brain. Ann Nucl Med. 2000;14:285–292
  23. Zhang MR, Haradahira T, Maeda J, Okauchi T, Kawabe K, Kida T, et al. Synthesis and evaluation of 2-(4-chlorobenzyl)-8-[11C]methoxy-1,2,3,4-tetrahydrochromeno[3,4-c]pyridine-5-one: a PET tracer for imaging sigma-1 receptors. Nucl Med Biol. 2002;29:469–476
  24. Shiba K, Ogawa K, Mori H. Characterization of radioiodinated (+)-2-[4-(4-iodophenyl)piperidino]cyclohexanol [(+)-pIV] as a sigma receptor ligand. Bioorg Med Chem. 2005;13(4):1095–1099
  25. Akhter N, Shiba K, Ogawa K, Kinuya S, Nakajima K, Mori H. In vivo characterization of radioiodinated (+)-2-[4-(4-iodophenyl)piperidino]cyclohexanol [(+)-pIV] as a potential sigma-1 receptor imaging agent. Nucl Med Biol. 2007;[in press]
  26. Ishiwata K, Kawamura K, Yajima K, Tu QGL, Mori H, Shiba K. Evaluation of (+)-p-[11C]methylvesamicol for mapping sigma-1 receptors: a comparison with [11C]SA4503. Nucl Med Biol. 2006;30:543–548
  27. McLean S, Weber E. Autoradiographic visualization of haloperidol-sensitive sigma receptors in guinea brain. Neuroscience. 1988;25:259–269
  28. Gundlach AL, Largent BL, Snyder SH. Autoradiographic localization of sigma receptor binding sites in guinea pig and rat central nervous system with (+)3H-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine. J Neuroscience. 1986;6(6):1757–1770
  29. Sadzot B, Price JC, Mayberg HS, Douglass KH, Dannals RF, Lever JR, et al. Quantification of human opiate receptor concentration and affinity using high and low specific activity [11C]diprenorphine and positron emission tomography. J Cereb Blood Flow Metab. 1991;11(2):204–219

PII: S0969-8051(07)00244-2

doi: 10.1016/j.nucmedbio.2007.09.005

Nuclear Medicine and Biology
Volume 35, Issue 1 , Pages 29-34 , January 2008

Article Tools

* Image Usage & Resolution